Halozyme Reports Record 2025 Revenue, Strategic Acquisitions, and Patent Win Amidst Profit Decline

summarizeSummary

Halozyme reported record 2025 revenue of $1.4 billion, up 37.5%, but net income fell 28.6% due to significant R&D expenses from acquisitions and asset impairment. The company also announced new collaborations, a patent win against Merck, and active capital management.

check_boxKey Events

• Full-Year 2025 Financial Results

  Reported record total revenue of $1.4 billion, a 37.5% increase year-over-year, driven by 52% growth in royalties and 24% growth in product sales. Despite this, net income decreased by 28.6% to $316.9 million, and diluted EPS decreased by 24.6% to $2.56, primarily due to significant acquired in-process R&D expenses and asset impairment charges.

• Strategic Acquisitions and Pipeline Expansion

  Completed the acquisitions of Elektrofi, Inc. (Hypercon technology) for $810.4 million and Surf Bio, Inc. (Surf Bio drug delivery technology) for $305.0 million, significantly expanding its drug delivery technology portfolio. The company also discontinued the ATRS-1902 program, resulting in a $48.7 million impairment charge.

• Key Product and Collaboration Milestones

  Achieved numerous regulatory approvals and expanded collaborations for its ENHANZE technology, including multiple approvals for Janssen's DARZALEX FASPRO/SC and RYBREVANT FASPRO, Roche's TECENTRIQ SC and OCREVUS SC, and argenx's VYVGART Hytrulo across various geographies and indications. A new global collaboration with Takeda for ENTYVIO was also initiated.

• Patent Infringement Lawsuit Against Merck

  A German court granted a preliminary injunction against Merck Sharp & Dohme Corp., ordering them to cease distributing and offering Keytruda SC in Germany, in connection with Halozyme's patent infringement lawsuit over its MDASE technology.

auto_awesomeAnalysis

Halozyme Therapeutics' 2025 annual report reveals robust top-line growth with record revenue of $1.4 billion, driven by strong performance in its ENHANZE technology and partner products. However, net income and diluted EPS saw a significant decline due to substantial acquired in-process research and development expenses from strategic acquisitions (Elektrofi and Surf Bio) and an impairment charge related to the discontinuation of a proprietary product. The company also actively managed its capital structure by issuing new convertible notes and repurchasing existing ones, alongside an ongoing share buyback program. A notable positive development is the preliminary injunction granted in Germany in its patent infringement lawsuit against Merck, which could protect its MDASE technology. Investors should weigh the strong underlying business growth and strategic expansion against the short-term impact on profitability and the CEO's planned share sales.